Sustainable East Africa Research in Community Health

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Antiretrovirals; Dolutegravir; Efavirenz
Indications HIV infections
Focus Therapeutic Use
Acronyms SEARCH

28 Feb 2024 According to a GSK media release, new findings from this trial will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3-6 March 2024.
16 Jan 2024 Results (n=43127) of a sub-study assessing whether a universal HIV-test-and-treat intervention reduced population-level incident TB infection in rural Uganda published in the Clinical Infectious Diseases
07 Feb 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com